23:17 , Jul 12, 2019 |  BC Extra  |  Financial News

HitGen joins growing Shanghai IPO queue

The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new science and technology innovation board. The small molecule discovery company proposed to sell at least 40 million shares and...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
19:02 , Jan 4, 2019 |  BC Week In Review  |  Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies identified a CDK7/CDK12/CDK13 inhibitor that could help treat ovarian cancer. Screening of 42 small molecules targeting transcriptional and/or epigenetic components in two human ovarian cancer cell lines...
20:10 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Mouse studies suggest IL-1RA and PRG4 gene therapy could help treat posttraumatic osteoarthritis. In a mouse model of ligament transection-induced posttraumatic osteoarthritis, intra-articular injection of IL-1RA and PRG4 encoded separately in helper-dependent adenoviral...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
16:52 , Oct 19, 2018 |  BC Extra  |  Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

A preprint article published in bioRxiv identified large cross-institutional batch effects for a subset of The Cancer Genome Atlas data. The report provides a warning to all multisite sequencing consortia, and calls for re-examining results...
16:19 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Publisher’s note: On Feb. 20, the authors of the Nature paper cited below retracted it due to issues with figure presentation and underlying data. Mouse studies suggest CAR T cells targeting ALCAM...
17:37 , Sep 21, 2018 |  BC Week In Review  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...